Answers are grounded in this paper and cite their sources.
Gallium-68 fibroblast activation protein inhibitor [( 68 Ga)Ga-FAPI] is a new radiopharmaceutical positioning itself as the preferred agent in patients with malignant tumours, competing with 2-Deoxy-2-[18F]fluoro-d-glucose [2-( 18 F)FDG] using positron emission tomography (PET). While imaging oncology patients with [ 68 Ga]Ga-FAPI PET, incidental uptake of [ 68 Ga]Ga-FAPI has been detected in the myocardium. This review summarises original research studies associating the visualisation of FAPI-based tracers in the myocardium with underlying active cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Mpanya et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: